E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Graft versus host disease |
|
E.1.1.1 | Medical condition in easily understood language |
Graft versus host disease is a process where donor cells may react against cells of your body causing inflammation that can involve the skin, liver and gastrointestinal system. |
|
E.1.1.2 | Therapeutic area | Not possible to specify |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10053239 |
E.1.2 | Term | Prophylaxis against graft versus host disease |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the effectiveness of 2GVHD prophylaxis regimens in preventing acute grades II-IV GVHD. |
|
E.2.2 | Secondary objectives of the trial |
1. Compare non-relapse mortality in the two arms. 2. Compare survival and progression-free survival in the two arms.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Ages >50 years with hematologic malignancies treatable by unrelated HCT.
Ages <= 50 years of age with hematologic diseases treatable by allogeneic HCT who through pre-existing medical conditions or prior therapy are considered to be at high risk for regimen related toxicity associated with a high dose transplant (>40% risk of TRM).
Ages <= 50 years of age with chronic lymphocytic leukemia (CLL) (these patients do not require patient review committee approvals).
Ages <= 50 years of age with hematologic diseases treatable by allogeneic HCT who refuse a high-dose HCT.
The following diseases will be permitted: 1) Aggressive nonHodgkin lymphomas (NHL) and Other Histologies Such as Diffuse large B cell NHL– not eligible for autologous HCT, not eligible for high-dose allogeneic HCT, or after failed autologous HCT. 2) Mantle Cell NHL -may be treated in first CR. 3) Low grade NHL– with < 6 month duration of CR between courses of conventional therapy 4) CLL – must have either 1) failed to meet NCI Working Group criteria for complete or partial response after therapy with a regimen containing FLU (or another nucleoside analog, e.g. 2-CDA, pentostatin) or experience disease relapse within 12 months after completing therapy with a regimen containing FLU (or another nucleoside analog); 2) failed FLU-CY-Rituximab (FCR) combination chemotherapy at any time point; or 3) have “17p deletion” cytogenetic abnormality. Patients should have received induction chemotherapy but could be transplanted in 1st CR; or 4) Patients with a diagnosis of CLL (or small lymphocytic lymphoma) or diagnosis of CLL that progresses to prolymphocytic leukemia (PLL), or T-cell CLL or PLL. 5) Hodgkin Lymphoma – must have received and failed frontline therapy. 6) Multiple Myeloma – must have received prior chemotherapy. Consolidation of chemotherapy by autografting prior to nonmyeloablative HCT is permitted. 7) Acute Myeloid Leukemia (AML)– must have < 5% marrow blasts at the time of transplant. 8) Acute Lymphocytic Leukemia (ALL) – must have <5% marrow blasts at the time of transplant. 9) Chronic Myeloid Leukemia (CML) – Patients will be accepted if they are beyond P1 and if they have received previous myelosuppressive chemotherapy or HCT, and have <5% marrow blasts at time of transplant. 10) Myelodysplasia(MDS)/Myeloproliferative Syndrome (MPS) – Patients must have <5% marrow blasts at time of transplant. 11) Waldenstrom’s Macroglobulinemia – must have failed 2 courses of therapy. |
|
E.4 | Principal exclusion criteria |
1) Patients with rapidly progressive intermediate or high grade NHL. 2) Patients with a diagnosis of CMML. 3) Patients with RAEB who have not received myelosuppressive chemotherapy i.e. induction chemotherapy. 4) CNS involvement with disease refractory to intrathecal chemotherapy. 5) Presence of circulating leukemic blasts (in the peripheral blood) detected by standard pathology for patients with AML, MDS, ALL or CML. 6) Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment. 7) Females who are pregnant or breast-feeding. 8) Patients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than 20% chance of having disease recurrence within 5 years. 9) Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month. 10) Organ dysfunction. a. Cardiac ejection fraction < 35%. Ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease. b. Pulmonary: i) DLCO < 40%, TLC <40%, FEV1 <40% and/or receiving supplementary continuous oxygen. ii) The FHCRC PI of the study must approve of enrollment of all patients with pulmonary nodules. c. Liver function abnormalities: Patients with clinical or laboratory evidence of liver disease would be evaluated for the cause of liver disease, its clinical severity in terms of liver function, and the degree of portal hypertension. 11) Karnofsky scores < 60 or Lansky Score <50 12) Patient has poorly controlled hypertension and on multiple antihypertensives 13) HIV positive patients. 14) Active bacterial or fungal infections unresponsive to medical therapy. 15) All patients receiving antifungal therapy voriconazole, posaconazole, or fluconazole and who are then randomized to ARM2 or ARM 3 must have sirolimus reduced. 16) The addition of cytotoxic agents for “cytoreduction” with the exception of tyrosine kinase inhibitors (such as imatinib), cytokine therapy, hydroxyurea, low dose cytarabine, chlorambucil, or rituxan will not be allowed within three weeks of the initiation of conditioning. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint for this trial will be the rate of acute grade II-IV GHVD at day 100 post-transplant, exclusive of GVHD that occurs as a result of alterations to immunosuppressive therapy in response to relapse or progression. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 150 patients have been randomized and evaluated for 100 days post-transplant, an interim analysis for futility will be conducted. This analysis will estimate the conditional power of the study, given the data available at that time and assuming that going forward the rates of GVHD will differ by 15% between arms, with the rates for each arm centered around the pooled estimate of the rate from the combined arms. The conditional power will be estimated by Monte Carlo simulation. If the estimated conditional power is <33.3% then the trial will be stopped, otherwise the trial will continue to completion. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints that will be analyzed include grade III-IV acute GVHD, chronic extensive GVHD, non-relapse mortality, relapse, and overall survival |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After 150 patients have been randomized and evaluated for 100 days post-transplant, an interim analysis for futility will be conducted. This analysis will estimate the conditional power of the study, given the data available at that time and assuming that going forward the rates of GVHD will differ by 15% between arms, with the rates for each arm centered around the pooled estimate of the rate from the combined arms. The conditional power will be estimated by Monte Carlo simulation. If the estimated conditional power is <33.3% then the trial will be stopped, otherwise the trial will continue to completion |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
After 150 patients have been randomized and evaluated for 100 days post-transplant, an interim analysis for futility will be conducted. If the estimated conditional power is <33.3% then the trial will be stopped, otherwise the trial will continue to completion. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |